stockrowHarmony Biosciences Holdings, Inc.
HRMY Healthcare Biotechnology
Harmony Biosciences Holdings, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $868.5 million, up 21.5% from fiscal 2024.
- Revenue
- +12.3%
- EPS
- −6.24%
- Free cash flow
- −29.4%
- Total debt
- −11.5%
Quarter to September 2026, against a year earlier
Follow HRMY
Alert me
Harmony Biosciences Holdings, Inc. (HRMY) P/B ratio
As of 6 November 2026, Harmony Biosciences Holdings, Inc. (HRMY) trades at a P/B ratio of 1.8×. Over the past ten years it has ranged from 0.0× (September 2020) to 17.6× (June 2021); the current reading is higher than 3% of that period. That is below the Biotechnology industry median of 2.1× and below the Healthcare sector median of 2.3×.
P/B ratio, daily
Embed this chart
Annual newest first
| Period | P/B ratio | Change |
|---|---|---|
| FY2025 | 2.5× | (16.75%) |
| FY2024 | 3.0× | (24.26%) |
| FY2023 | 3.9× | (49.60%) |
| FY2022 | 7.8× | (40.86%) |
| FY2021 | 13.2× | 37.20% |
| FY2020 | 9.6× | — |
| FY2019 | 0.0× | — |
Quarterly newest first
| Period | P/B ratio | Change |
|---|---|---|
| Sep 2026 | 2.1× | 1.31% |
| Jun 2026 | 2.1× | 18.66% |
| Mar 2026 | 1.8× | (28.04%) |
| Dec 2025 | 2.5× | 30.17% |
| 23 more quarters | Free account |
Against its own ten years
P/B ratio against peers
| Company | P/B ratio |
|---|---|
| SRPT Sarepta Therapeutics, Inc. compare | 1.2× |
| HRMY Harmony Biosciences Holdings, Inc. | 1.8× |
| MESO Mesoblast Limited compare | 1.9× |
| VIR Vir Biotechnology, Inc. compare | 2.3× |
| FTRE Fortrea Holdings Inc. compare | 3.9× |
| MAZE Maze Therapeutics, Inc. compare | 4.5× |
| TRVI Trevi Therapeutics, Inc. compare | 6.9× |
| REPL Replimune Group, Inc. compare | 11.2× |
| TRAX First Tracks Biotherapeutics, Inc. compare | 11.3× |
| Biotechnology industry median | 2.1× |
| Healthcare sector median | 2.3× |
| Market median | 1.7× |
What P/B ratio is
Price to Book Value tells an investor how much the market pays for a company’s shares relative to the accounting net worth that belongs to common shareholders.
Stock Price ÷ (Common Equity (Total) (latest quarter) ÷ Shares (Basic, Weighted) (latest quarter))